Product Information
DIOVAN HCT 160-25 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $13.0470 per EA under NDC 00078038334. Its NADAC has been published 283 times since Nov 28, 2013.
FDA first approved this application on Mar 6, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the valsartan and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25; 160 mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078038334
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/7/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA020818FDA Approved
3/6/1998
TE Code
AB
On Market Since
3/6/1998
Pharmacological Classes
Price Statistics
The NADAC for DIOVAN HCT 160-25 MG TABLET has been published 283 times since Nov 28, 2013, and over the history we have for it it has risen 171.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.0470 per EA |
|---|---|
| All-time high | $13.0470 (Mar 11, 2026) |
| All-time low | $4.8108 (Nov 28, 2013) |
| 52-week high | $13.0470 |
| 52-week low | $12.6670 |
| Median price | $7.6578 |
| Average price | $8.6192 |
| Largest weekly change | +48.3% (Aug 21, 2024) |
| Weeks tracked | 283 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
+3.0%
3Y
+56.2%
5Y
+56.2%
All
+171.2%
Last surveyed Mar 11, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DIOVAN HCT 160-25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DIOVAN HCT 160-25 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $13.0470 per EA (NDC 00078038334), effective Mar 11, 2026.
How has the price of DIOVAN HCT 160-25 MG TABLET changed over time?
Over the history we have for it, the NADAC for DIOVAN HCT 160-25 MG TABLET has risen 171.2%. It has been tracked across 283 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DIOVAN HCT 160-25 MG TABLET?
Since Nov 28, 2013, the NADAC for DIOVAN HCT 160-25 MG TABLET has ranged from a low of $4.8108 (Nov 28, 2013) to a high of $13.0470 (Mar 11, 2026), with a median of $7.6578 per EA.
Are there cheaper alternatives to DIOVAN HCT 160-25 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VALSARTAN-HYDROCHLOROTHIAZIDE 160-25 MG TAB, is $0.1245 per EA — about 99% below DIOVAN HCT 160-25 MG TABLET.
Who manufactures DIOVAN HCT 160-25 MG TABLET?
DIOVAN HCT 160-25 MG TABLET (NDC 00078038334) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.